# Navarre Institute of Health Research

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/navarre-institute-of-health-research/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 82 |
| Citations | 597,818 |
| City | Pamplona |
| Country | ES |
| Description | Navarre Institute of Health Research is a research organisation in Pamplona, ES. OpenAlex records 6,933 works and 597,818 citations for it. 1,727 researchers list it as their most recent affiliation. |
| Homepage | https://www.idisna.es |
| OpenAlex ID | https://openalex.org/I4210112085 |
| Region | Navarre |
| Researchers | 1,727 |
| ROR ID | https://ror.org/023d5h353 |
| Type | education |
| Works | 6,933 |

## University papers

Showing 12 of 15.

- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease](https://scholariq.org/papers/standardized-rt-pcr-analysis-of-fusion-gene-transcripts-from-chromosome/)
- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/ide-cel-or-standard-regimens-in-relapsed-and-refractory-multiple-myeloma/)
- [Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma](https://scholariq.org/papers/talquetamab-a-t-cell-redirecting-gprc5d-bispecific-antibody-for-multiple-myeloma/)
- [Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results](https://scholariq.org/papers/elranatamab-in-relapsed-or-refractory-multiple-myeloma-phase-2-magnetismm-3/)
- [Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma](https://scholariq.org/papers/daratumumab-bortezomib-lenalidomide-and-dexamethasone-for-multiple-myeloma/)
- [Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study](https://scholariq.org/papers/teclistamab-a-b-cell-maturation-antigen-cd3-bispecific-antibody-in-patients-with/)
- [Epigenetic Silencing of the Tumor Suppressor MicroRNA <i>Hsa-miR-124a</i> Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia](https://scholariq.org/papers/epigenetic-silencing-of-the-tumor-suppressor-microrna-i-hsa-mir-124a-i-regulates/)
- [LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma](https://scholariq.org/papers/locommotion-a-prospective-non-interventional-multinational-study-of-real-life/)
- [A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial](https://scholariq.org/papers/a-simplified-frailty-scale-predicts-outcomes-in-transplant-ineligible-patients/)

## University researchers

- [Paula Rodríguez‐Otero](https://scholariq.org/researchers/paula-rodriguez-otero/)

## University top topics

Showing 8 of 25.

- [Nutritional Studies and Diet](https://scholariq.org/topics/nutritional-studies-and-diet/)
- [Diet and metabolism studies](https://scholariq.org/topics/diet-and-metabolism-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Obesity, Physical Activity, Diet](https://scholariq.org/topics/obesity-physical-activity-diet/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Schizophrenia research and treatment](https://scholariq.org/topics/schizophrenia-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.